The GATA1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblastoid cell line, featuring targeted disruption of the GATA1 gene to generate a loss-of-function model. This polyclonal product maintains a heterogeneous genetic background, offering a robust tool for studying GATA1 function without clonal selection artifacts. The knockout cells are supplied in a suspension format, reflecting the native growth properties of the parental Raji line, and are suitable for a wide range of downstream molecular and cellular assays.
The host Raji cell line is a human B lymphoblastoid suspension line originating from a Burkitt lymphoma, and it is Epstein-Barr virus (EBV)-positive. Raji cells are widely employed in immunology and cancer biology research due to their capacity for antibody production and their role in immune response studies. The lymphoblastoid nature and rapid proliferation of Raji cells make them an ideal chassis for investigating gene function in a lymphoid context, particularly for genes not typically expressed in this lineage, enabling ectopic and off-target effect studies.
GATA1 encodes a zinc-finger transcription factor that binds GATA motifs in DNA to activate or repress target gene expression. It is a master regulator of erythropoiesis and megakaryopoiesis, essential for terminal differentiation of these lineages. GATA1 functions downstream of signaling cascades including erythropoietin (EPO)-EPO receptor (EPOR)-JAK2-STAT5, where STAT5 directly activates GATA1 transcription. GATA1 also interacts with cofactors such as ZFPM1 (FOG1), TAL1, LMO2, and LDB1 to form transcriptional complexes, while associating with HDAC1 and HDAC2 for repression. It transcriptionally regulates critical downstream targets including HBB (hemoglobin subunit beta), ALAS2 (heme biosynthesis), SLC4A1 (band 3 anion exchanger), EPB42 (protein 4.2), and GYPA (glycophorin A), while repressing MYB and KIT to enforce lineage commitment.
In the Raji lymphoid environment, GATA1 knockout provides a unique platform to explore lineage-inappropriate gene functions and cross-lineage regulatory mechanisms. Although GATA1 is not natively expressed in B cells, its disruption may reveal cryptic regulatory networks or synthetic lethal interactions relevant to hematological malignancies such as acute megakaryoblastic leukemia and myelodysplastic syndromes, where GATA1 mutations are implicated. The EBV-positive background further enables studies on viral latency and oncogenic cooperation. This model is particularly valuable for dissecting how GATA1 loss influences B-cell physiology, apoptosis, or differentiation program misregulation.
Typical research applications include investigation of GATA1 function in lymphoid cells, disease modeling of GATA1-related disorders, screening for small molecule modulators, and CRISPR gene regulation studies. The knockout cells are amenable to representative techniques such as Western blotting, RT-qPCR, RNA-seq, ChIP-qPCR, flow cytometry, and luciferase reporter assays. These assays facilitate validation of GATA1 target gene expression changes, protein interaction disruptions, and functional rescue experiments. For further details or custom inquiries, please contact Ascent Research.
